PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield
New Jersey
07080-2449
United States
Website: http://www.ptcbio.com/
566 articles with PTC Therapeutics, Inc.
-
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - March 28, 2023
3/28/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 22, 2023 , the company approved non-statutory stock options to purchase an aggregate of 58,465 shares of its common stock and 29,710 restricted stock units ("RSUs").
-
Upstaza is the first targeted therapy for aromatic L-amino acid decarboxylase (AADC) deficiency. PTC expects to submit a Biologics License Application to the FDA in the first half of 2023.
-
Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics
3/24/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT ). Stuart Peltz , Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced today that he is stepping down after 25 years.
-
PTC Therapeutics reported Q4 and full-year 2022 results Tuesday ahead of a pivotal 2023 featuring three late-stage readouts in registration-directed trials.
-
PTC Therapeutics to Participate at Upcoming Investor Conferences - February 21, 2023
2/21/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences.
-
PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
2/21/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2022.
-
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
2/7/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2022 financial results and provide an update on the company's business and outlook on Tuesday, Feb. 21, at 4:30 p.m. ET.
-
PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation
2/3/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of 2023 EURORDIS Black Pearl Company Award for Innovation.
-
PTC Therapeutics to Participate at Upcoming Investor Conference - February 02, 2023
2/2/2023
PTC Therapeutics, Inc. announced that the company will present a company overview at the following conference.
-
NICE Recommends Reimbursement for Translarna™
1/19/2023
PTC Therapeutics, Inc. announced that the National Institute for Health and Care Excellence has issued a Final Evaluation Document recommending Translarna™ for reimbursement and use across the National Health Service in England and Wales.
-
PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community
1/17/2023
PTC Therapeutics, Inc. announced the launch of the ninth annual STRIVE™ awards program.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 11, 2023
1/11/2023
PTC Therapeutics, Inc. announced that on Jan. 5, 2023, the company approved non-statutory stock options to purchase an aggregate of 39,585 shares of its common stock and 13,045 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 33 new employees.
-
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference
1/9/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 41st Annual J.P. Morgan Healthcare Conference today, Monday January 9, at 10:30am EST/7:30am PST.
-
PTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, Jan. 9, at 7:30 a.m. PST/10:30 a.m. EST.
-
Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy
12/1/2022
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra™ (volanesorsen) as the first treatment for familial partial lipodystrophy (FPL) in Brazil.
-
Upstaza™ Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
11/17/2022
PTC Therapeutics, Inc. today announced that Upstaza™ (eladocagene exuparvovec) was granted authorization by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain.
-
Huntington’s disease might just top the list of intractable neurodegenerative diseases. BioSpace spoke with the field's foremost experts about the challenges and how to overcome them.
-
BioAge Labs, PTC Therapeutics, Biogen and others highlighted novel mechanisms targeting newer pathways in neurodegenerative diseases at the recent Discovery on Target meeting.
-
PTC Therapeutics forged a financing deal valued at up to $1 billion with Blackstone that will allow it to deliver one new therapy every two or three years, the New Jersey-based biotech reported.
-
PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results
10/27/2022
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2022.